| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 1938 | 2017 |
| Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer BS Carver, C Chapinski, J Wongvipat, H Hieronymus, Y Chen, ... Cancer cell 19 (5), 575-586, 2011 | 1305 | 2011 |
| ESR1 ligand-binding domain mutations in hormone-resistant breast cancer W Toy, Y Shen, H Won, B Green, RA Sakr, M Will, Z Li, K Gala, S Fanning, ... Nature genetics 45 (12), 1439-1445, 2013 | 1216 | 2013 |
| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ... Cancer cell 19 (1), 58-71, 2011 | 1061 | 2011 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 798 | 2018 |
| Unlocking the potential of antibody–drug conjugates for cancer therapy JZ Drago, S Modi, S Chandarlapaty Nature Reviews Clinical Oncology 18 (6), 327-344, 2021 | 605 | 2021 |
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ... Oncogene 30 (22), 2547-2557, 2011 | 600 | 2011 |
| Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas P Lito, CA Pratilas, EW Joseph, M Tadi, E Halilovic, M Zubrowski, ... Cancer cell 22 (5), 668-682, 2012 | 592 | 2012 |
| Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer G Schiavon, S Hrebien, I Garcia-Murillas, RJ Cutts, A Pearson, ... Science translational medicine 7 (313), 313ra182-313ra182, 2015 | 574 | 2015 |
| HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies D Gajria, S Chandarlapaty Expert review of anticancer therapy 11 (2), 263-275, 2011 | 574 | 2011 |
| mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ... Cancer discovery 1 (3), 248-259, 2011 | 515 | 2011 |
| HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing … S Modi, A Stopeck, H Linden, D Solit, S Chandarlapaty, N Rosen, ... Clinical Cancer Research 17 (15), 5132-5139, 2011 | 492 | 2011 |
| Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial S Chandarlapaty, D Chen, W He, P Sung, A Samoila, D You, T Bhatt, ... JAMA oncology 2 (10), 1310-1315, 2016 | 470 | 2016 |
| Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline SH Giordano, S Temin, JJ Kirshner, S Chandarlapaty, JR Crews, ... Journal of clinical oncology 32 (19), 2078, 2014 | 456 | 2014 |
| Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ... Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011 | 372 | 2011 |
| Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway Z Li, P Razavi, Q Li, W Toy, B Liu, C Ping, W Hsieh, F Sanchez-Vega, ... Cancer cell 34 (6), 893-905. e8, 2018 | 364 | 2018 |
| Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling QB She, S Chandarlapaty, Q Ye, J Lobo, KM Haskell, KR Leander, ... PloS one 3 (8), e3065, 2008 | 352 | 2008 |
| Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence C Yang, Z Li, T Bhatt, M Dickler, D Giri, M Scaltriti, J Baselga, N Rosen, ... Oncogene 36 (16), 2255-2264, 2017 | 351 | 2017 |
| PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ... Science translational medicine 7 (283), 283ra51-283ra51, 2015 | 341 | 2015 |
| Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists W Toy, H Weir, P Razavi, M Lawson, AU Goeppert, AM Mazzola, A Smith, ... Cancer discovery 7 (3), 277-287, 2017 | 336 | 2017 |
